ImmunityBio Stock Soars 295% YTD: Time to Buy, Hold or Sell?

Core Viewpoint - ImmunityBio's stock (IBRX) has surged nearly 300% year to date, significantly outperforming the industry and S&P 500, driven by strong demand for its product Anktiva [2][9]. Financial Performance - ImmunityBio reported net product revenues of $113 million for the full year 2025, reflecting a 700% increase year over year, primarily due to repeat prescriptions of Anktiva [7][9]. - The ongoing shortage of Bacillus Calmette-Guérin (BCG) has created treatment bottlenecks, further boosting demand for Anktiva [8]. Product Development and Regulatory Approvals - Anktiva has received regulatory approvals in the EU and Saudi Arabia for treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) [11]. - The company is pursuing additional label expansions for Anktiva, including a recent resubmission to the FDA for a combination therapy with BCG [10][12]. - ImmunityBio is also exploring Anktiva's potential in non-small cell lung cancer (NSCLC) and other oncology indications, with ongoing clinical studies aimed at expanding its therapeutic applications [12][14][15]. Competitive Landscape - ImmunityBio faces significant competition from established pharmaceutical companies like Merck, Bristol Myers, and Roche, which have well-established products and resources in the oncology market [18][19]. - The competitive pressure may challenge ImmunityBio's market penetration despite the promising growth trajectory of Anktiva [26]. Valuation and Market Position - ImmunityBio's stock is trading at a premium, with a price-to-sales (P/S) ratio of 32.59, compared to the industry average of 2.00 [22]. - Despite the high valuation, the early commercial performance of Anktiva suggests potential for continued revenue growth [26].